FDA Approved: XTANDI — Supplemental Application (Astellas Pharma US, Inc.)

View source ↗

Summary

FDA approved a supplemental NDA for XTANDI (enzalutamide) submitted by Astellas Pharma US, Inc., to update the labeling and/or expand an indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Xtandi (enzalutamide)

Snippet

SUPPL AP for XTANDI (ENZALUTAMIDE)